MBX Biosciences Files S-1 for Public Offering
Ticker: MBX · Form: S-1 · Filed: Aug 23, 2024 · CIK: 1776111
Sentiment: neutral
Topics: ipo, s-1, pharmaceutical
TL;DR
MBX Biosciences just filed its S-1, looks like they're gearing up for an IPO.
AI Summary
MBX Biosciences, Inc., a Delaware-based pharmaceutical company, filed an S-1 registration statement on August 23, 2024, to register its securities for public offering. The company, located at 12406 Horesham Street, Carmel, Indiana, is seeking to raise capital through this filing. The filing details its business operations and financial structure as it prepares for a potential IPO.
Why It Matters
This S-1 filing indicates MBX Biosciences is preparing to go public, which could bring new investment into the pharmaceutical sector and potentially lead to the development of new treatments.
Risk Assessment
Risk Level: medium — As an S-1 filing, it represents a company in the process of going public, which inherently carries market and execution risks.
Key Numbers
- 333-281764 — SEC File Number (Identifies the specific registration statement with the SEC.)
- 1231 — Fiscal Year End (Indicates the end of the company's annual accounting period.)
Key Players & Entities
- MBX Biosciences, Inc. (company) — Registrant
- August 23, 2024 (date) — Filing Date
- 12406 Horesham Street, Carmel, Indiana (address) — Principal Business Address
- P. Kent Hawryluk (person) — President and Chief Executive Officer
- Goodwin Procter LLP (company) — Legal Counsel
FAQ
What is the primary purpose of this S-1 filing for MBX Biosciences, Inc.?
The S-1 filing is a registration statement required by the SEC for companies intending to offer securities to the public, indicating MBX Biosciences' preparation for an Initial Public Offering (IPO).
When was the S-1 filing submitted to the SEC?
The S-1 filing was submitted to the Securities and Exchange Commission on August 23, 2024.
Where is MBX Biosciences, Inc. headquartered?
MBX Biosciences, Inc.'s principal executive offices are located at 11711 N. Meridian Street, Suite 300, Carmel, Indiana 46032.
Who is listed as the President and Chief Executive Officer of MBX Biosciences, Inc.?
P. Kent Hawryluk is listed as the President and Chief Executive Officer of MBX Biosciences, Inc.
What is the Standard Industrial Classification (SIC) code for MBX Biosciences, Inc.?
The Standard Industrial Classification (SIC) code for MBX Biosciences, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 4,383 words · 18 min read · ~15 pages · Grade level 16.9 · Accepted 2024-08-23 16:44:42
Filing Documents
- d790774ds1.htm (S-1) — 2274KB
- d790774dex31.htm (EX-3.1) — 139KB
- d790774dex33.htm (EX-3.3) — 68KB
- d790774dex41.htm (EX-4.1) — 177KB
- d790774dex42.htm (EX-4.2) — 10KB
- d790774dex101.htm (EX-10.1) — 364KB
- d790774dex108.htm (EX-10.8) — 258KB
- d790774dex109.htm (EX-10.9) — 248KB
- d790774dex211.htm (EX-21.1) — 1KB
- d790774dex231.htm (EX-23.1) — 1KB
- d790774dexfilingfees.htm (EX-FILING FEES) — 20KB
- g790774g00a06.jpg (GRAPHIC) — 71KB
- g790774g00m01.jpg (GRAPHIC) — 50KB
- g790774g00s44.jpg (GRAPHIC) — 164KB
- g790774g02s97.jpg (GRAPHIC) — 118KB
- g790774g14v41.jpg (GRAPHIC) — 86KB
- g790774g40a82.jpg (GRAPHIC) — 170KB
- g790774g43a01.jpg (GRAPHIC) — 112KB
- g790774g48m48.jpg (GRAPHIC) — 90KB
- g790774g59i17.jpg (GRAPHIC) — 89KB
- g790774g70y95.jpg (GRAPHIC) — 144KB
- g790774g72d51.jpg (GRAPHIC) — 78KB
- g790774g75h77.jpg (GRAPHIC) — 114KB
- g790774g75q33.jpg (GRAPHIC) — 58KB
- g790774g77b51.jpg (GRAPHIC) — 125KB
- g790774g80i17.jpg (GRAPHIC) — 90KB
- g790774g80w10.jpg (GRAPHIC) — 89KB
- g790774g83a26.jpg (GRAPHIC) — 83KB
- g790774g84m86.jpg (GRAPHIC) — 167KB
- g790774page015.jpg (GRAPHIC) — 416KB
- g790774page016.jpg (GRAPHIC) — 151KB
- 0001193125-24-206227.txt ( ) — 6955KB
Risk factors
Risk factors 16 Special note regarding forward-looking statements 94
Use of proceeds
Use of proceeds 96 Dividend policy 98 Capitalization 99
Managements discussion and analysis of financial condition and results of operations
Managements discussion and analysis of financial condition and results of operations 104
Business
Business 122 Management 168
Executive compensation
Executive compensation 178 Certain relationships and related person transactions 190 Principal stockholders 195
Description of capital stock
Description of capital stock 198 Shares eligible for future sale 204 Material U.S. federal income tax considerations for non-U.S. holders 206
Underwriting
Underwriting 210 Legal matters 224 Experts 224 Where you can find more information 224 Index to financial statements F-1 We have not, and the underwriters have not, authorized anyone to provide any information or to make any representation other than those contained in this prospectus, any amendment or supplement to this prospectus or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares of common stock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus, any amendment or supplement to this prospectus or any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside the United States: We have not, and the underwriters have not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside the United States. i Table of Contents Market data and certain other statistical information used throughout this prospectus are based on independent industry publications, governmental publications, reports by market research firms, or other independent sources that we believe to be reliable sources. Industry publications and third-party research, surv